@Article{ravinetto_predictable_2016,
  title = {Predictable threats to public health through delaying universal access to innovative medicines for hepatitis C: a pharmaceutical standpoint},
  volume = {21},
  issn = {1365-3156},
  doi = {10.1111/tmi.12784},
  shorttitle = {Predictable threats to public health through delaying universal access to innovative medicines for hepatitis C},
  pages = {1490--1495},
  number = {12},
  journaltitle = {Tropical medicine \& international health: {TM} \& {IH}},
  shortjournal = {Trop. Med. Int. Health},
  author = {Raffaella Ravinetto and Anja {De Weggheleire} and Thomas P. C. Dorlo and Sven Francque and An Sokkab and Corinne Pouget and Bruno Meessen and Patricia Tabernero and Paul N. Newton and Lut Lynen},
  date = {2016-01-01},
  pmid = {27671365},
  keywords = {access to medicines, Anilides, Antiviral Agents, Benzimidazoles, Carbamates, counterfeit medicines, Drug Industry, Drug Therapy, Combination, essential medicines, Fees, Pharmaceutical, Fluorenes, Health Services Accessibility, hepatitis C, Hepatitis C, Chronic, Humans, Imidazoles, Macrocyclic Compounds, Public Health, Quality Assurance, Health Care, Quality Control, quality of medicines, Ritonavir, Simeprevir, Sofosbuvir, substandard medicines, Sulfonamides, Uracil, Uridine Monophosphate},
  file = {Full Text:C\:\\Users\\thoma\\Zotero\\storage\\RSJB9H7R\\Ravinetto et al. - 2016 - Predictable threats to public health through delay.pdf:application/pdf},
  pmcid = {PMC5244681},
}
